Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1450-1457

  Grünwald, Geoffrey K ^a   Vetter, Alexandra ^b   Klutz, Kathrin ^a   Willhauck, Michael J ^a   Schwenk, Nathalie ^a   Senekowitsch Schmidtke, Reingard ^c   Schwaiger, Markus ^c   Zach, Christian ^a   Wagner, Ernst ^b   Göke, Burkhard ^a   Holm, Per S ^c   Ogris, Manfred ^b   Spitzweg, Christine ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adenovirus serotype 5; Gene therapy; PAMAM dendrimer; Radiovirotherapy; Sodium iodide symporter (NIS)

Indexed keywords

ADENOVIRUS VECTOR; DENDRIMER; NEUTRALIZING ANTIBODY; POLYAMIDOAMINE; SODIUM IODIDE SYMPORTER;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE; GENE EXPRESSION; GENE THERAPY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MOUSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SCINTIGRAPHY; THERANOSTIC GENE; VIROTHERAPY; VIRUS PARTICLE; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRUS SEROTYPE 5; GENE THERAPY; PAMAM DENDRIMER; RADIOVIROTHERAPY; SODIUM IODIDE SYMPORTER (NIS);

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; DENDRIMERS; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MICE; ONCOLYTIC VIROTHERAPY; RADIOTHERAPY, IMAGE-GUIDED; SYMPORTERS; TRANSDUCTION, GENETIC;

EID: 84881433261     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.115493     Document Type: Article

References (35)

1. Duffy MR, Parker AL, Bradshaw AC, Baker AH. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine (Lond). 2012;7:271-288.
2. Baril P, Martin-Duque P, Vassaux G. Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy. Br J Pharmacol. 2010;159:761-771.
3. Grünwald GK, Klutz K, Willhauck MJ, et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus. Gene Ther. 2013;20:625-633.
4. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther. 2008;16: 16-29.
5. Yao XL, Nakagawa S, Gao JQ. Current targeting strategies for adenovirus vectors in cancer gene therapy. Curr Cancer Drug Targets. 2011;11:810-825.
6. Laga R, Carlisle R, Tangney M, Ulbrich K, Seymour LW. Polymer coatings for delivery of nucleic acid therapeutics. J Control Release. 2012;161:537-553.
7. Vetter A, Virdi KS, Espenlaub S, et al. Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor. Mol Pharm. 2013;10:606-618.
8. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001;8:1524-1531.
9. Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoterdriven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999;59:2136-2141.
10. Unterholzner S, Willhauck MJ, Cengic N, et al. Dexamethasone stimulation of retinoic acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells. J Clin Endocrinol Metab. 2006;91:69-78.
11. Willhauck MJ, Sharif Samani BR, Gildehaus FJ, et al. Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab. 2007;92:4451-4458.
12. Klutz K, Schaffert D, Willhauck MJ, et al. Epidermal growth factor receptortargeted 131I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol Ther. 2011;19:676-685.
13. Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf). 2002;57:559-574.
14. Klutz K, Russ V, Willhauck MJ, et al. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Clin Cancer Res. 2009;15:6079-6086.
15. Klutz K, Willhauck MJ, Dohmen C, et al. Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene. Hum Gene Ther. 2011;22:1563-1574.
16. Kang E, Yun CO. Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity. BMB Rep. 2010;43:781-788.
17. Navarro G, Maiwald G, Haase R, et al. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery. J Control Release. 2010;146:99-105.
18. Hart LS, Yannone SM, Naczki C, et al. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. J Biol Chem. 2005;280:1474-1481.
19. Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: radiationenhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys. 2006;66: 637-646.
20. Hingorani M, White CL, Zaidi S, et al. Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res. 2008;14:4915-4924.
21. Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ. Genetically targeted radiotherapy for multiple myeloma. Blood. 2003;102:489-496.
22. Wapnir IL, Goris M, Yudd A, et al. The Na1/I-symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 2004;10:4294-4302.
23. Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999;59:661-668.
24. Valenta L. Metastatic thyroid carcinoma in man concentrating iodine without organification. J Clin Endocrinol Metab. 1966;26:1317-1324.
25. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004;103:1641-1646.
26. Goel A, Carlson SK, Classic KL, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood. 2007;110: 2342-2350.
27. Hakkarainen T, Rajecki M, Sarparanta M, et al. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clin Cancer Res. 2009;15:5396-5403.
28. Peerlinck I, Merron A, Baril P, et al. Targeted radionuclide therapy using a Wnttargeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res. 2009;15:6595-6601.
29. Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther. 2010;17:1325-1332.
30. Haddad D, Zanzonico PB, Carlin S, et al. A vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer. J Nucl Med. 2012;53:1933-1942.
31. Kasman LM, Barua S, Lu P, Rege K, Voelkel-Johnson C. Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. Mol Pharm. 2009;6:1612-1619.
32. Davis HE, Rosinski M, Morgan JR, Yarmush ML. Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J. 2004;86:1234-1242.
33. Green NK, Herbert CW, Hale SJ, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004;11:1256-1263.
34. Prill JM, Espenlaub S, Samen U, et al. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol Ther. 2011;19:83-92.
35. Kim PH, Sohn JH, Choi JW, et al. Active targeting and safety profile of PEGmodified adenovirus conjugated with Herceptin. Biomaterials. 2011;32:2314-2326.